Pacfic Shuanglin Bio-Pharmacy (000403.SZ) accepted investor surveys on September 26, 2024 regarding "How to control the risks of centralized blood product procurement?" The company stated that the blood product industry has experienced several rounds of centralized procurement, and since 2022, the main products have all been subject to centralized procurement. Overall, the blood product industry has relatively tight overall supply and high industry barriers, with centralized procurement having a relatively small impact on the industry.
派林生物(000403.SZ)：集采对血液制品行业影响相对较小
Pacific Shuanglin Bio-Pharmacy (000403.SZ): The impact of centralized procurement on the blood products industry is relatively small.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.